Polysaccharide antigen–carrier protein conjugate (None widely used)

Polysaccharide antigen–carrier protein conjugates are engineered vaccine immunogens in which a surface carbohydrate antigen from a pathogen (such as a capsular polysaccharide) is covalently linked to a carrier protein (such as diphtheria toxoid, tetanus toxoid, or CRM197)[1][3][4][5][7]. Alone, polysaccharide antigens are poor inducers of long-lived, memory immune responses, especially in infants, because they do not engage T cells effectively. When conjugated to a carrier protein, the resulting compound can be processed by antigen-presenting cells; peptides from the carrier are presented on MHC class II to T helper cells, allowing for affinity maturation, isotype switching, and generation of high-quality, long-lived antibody responses[1][3][5][6][7]. This principle underlies the effectiveness of several widely used conjugate vaccines against bacterial pathogens. The conjugate itself is not an endogenous "target" but a synthetic immunogen formulation. There are important considerations in carrier protein selection to avoid suppression or interference with the immune response due to overlapping use in multiple vaccines[4]. If you need information about a specific carrier protein or polysaccharide antigen, individual names would be required for structured target mapping.

Other names

Glycoconjugate antigenGlycoconjugate vaccineConjugate vaccinePolysaccharide–protein conjugate

Covalent linkage of polysaccharide to carrier protein allows the polysaccharide to be processed and presented via MHC class II, enabling T cell–dependent immune responses and immunological memory